Understanding the divergent functions of mutant p53
Understanding the divergent functions of mutant p53
批准号:
10533928
负责人:
Margaret Kennedy
金额:
$4.68万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-07-01 至 2025-06-30
关键词:
AddressAdoptedAffectAllelesBindingBiological AssayBiomedical ResearchCancer PatientCell LineCell physiologyCellsCellular biologyChIP-seqChromatinClustered Regularly Interspaced Short Palindromic RepeatsCoupledCouplesDNADNA Binding DomainDataDevelopmentDisease modelDoxycyclineDuctal Epithelial CellEngineeringGene ExpressionGenerationsGenetic TranscriptionGoalsGuide RNAHumanImpairmentIn VitroIndividualLaboratoriesMalignant - descriptorMalignant NeoplasmsMentorsMissense MutationMolecularMolecular BiologyMusMutateMutationNeoplasm MetastasisOncogenicPancreatic Ductal AdenocarcinomaPancreatic ductPathway interactionsPatientsPatternPhenotypePlant RootsPropertyProteinsPublishingRecurrenceRenillaReportingRoleSamplingTP53 geneTestingThe Cancer Genome AtlasTissue-Specific Gene ExpressionTrainingTumor Suppressor GenesTumor-DerivedVariantWorkbase editingbiobankcareergain of functionin vivometastatic processmouse modelmutantnovel strategiespancreatic cancer patientspancreatic ductal adenocarcinoma modelpancreatic neoplasmprogramssingle-cell RNA sequencingskillssmall hairpin RNAtranscription factortranscriptometranscriptome sequencingtranscriptomicstreatment strategytumortumorigenicvirtual
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Mutation of the TP53 tumor suppressor gene is the most common genetic alteration in cancer, and over 100
distinct and recurrent missense mutations in TP53 have been identified. Virtually all p53 mutants studied to date
have lost the ability to bind to DNA, thereby impairing its function as a transcription factor, and it seems likely
that this molecular function largely explains its role in tumor formation. Additionally, many studies have
uncovered gain-of-function or oncogenic properties of individual mutants that extend beyond loss of wild type
function, most notably the ability to promote invasion and metastasis. Nevertheless, which specific TP53
mutations drive differential tumor development and the molecular mechanisms responsible for these phenotypes
remain poorly understood. Given that p53 is a transcription factor and that a significant fraction of cancer-
associated mutations, including C132Y, occur in the DNA binding domain, I hypothesize that p53 mutants
promote differential tumor formation and progression by profoundly altering the cellular transcriptome in a
mutant-specific manner.
Aim 1: Characterize the metastatic potential of p53 C132Y mutant. In preliminary studies, I identified the
cancer associated mutation, C132Y, as an allele that has greater metastatic potential than other mutants. In this
aim, I propose in vitro and in vivo functional characterization of this mutant with the goal of determining: 1)
whether the mutant is necessary for metastasis and 2) the molecular mechanisms by which the mutant promotes
metastasis.
Aim 2: Systematic characterization of p53 missense mutants. Many studies, including some from our own
lab, have produced data to suggest that there may be differences in the function of unique missense mutant p53
proteins. What these functions are and to what extent they are conserved between mutants is still poorly
understood. To address this question, I propose: 1) a systematic characterization of the transcriptome of cells
harboring different mutant p53 proteins and 2) a detailed characterization of the top two mutants from each
transcriptional cluster to probe the mechanisms by which the mutants are functioning.
Training Plan: The applicant will work with an interdisciplinary team of mentors and collaborators to gain
expertise in cell and molecular biology, precision mouse models of disease, and generation and analysis of
transcriptomic data. The skills that the applicant will develop during this project will serve her well over the course
of her career in biomedical research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Understanding the divergent functions of mutant p53
-
批准号:10661541
-
项目类别:
-
资助金额:$4.77万
-
财政年份:2022
-
负责人:Margaret Kennedy
-
依托单位:
海外基金